The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu, China.
Hum Vaccin Immunother. 2022 Nov 30;18(5):2060019. doi: 10.1080/21645515.2022.2060019. Epub 2022 Apr 25.
Cervical cancer is one of the most common malignancies among females. As a virus-related cancer, cervical cancer has attracted a lot of attention to develop virus-targeted immune therapy, including vaccine and adoptive immune cell therapy (ACT). Adoptive tumor infiltrating lymphocytes (TILs) cell therapy has been found to be able to control advanced disease progression in some cervical cancer patients who have received several lines of treatment in a pilot clinical trial. In addition, sustainable therapeutic effect has been identified in some cases. The safety risks of TIL therapy for patients are minimal or at least manageable. In this review, we focused on the versatility of TILs and tried to summarize potential strategies to improve the therapeutic effect of TILs and discuss related perspectives.
宫颈癌是女性最常见的恶性肿瘤之一。作为一种与病毒相关的癌症，宫颈癌引起了人们的广泛关注，以开发针对病毒的免疫治疗方法，包括疫苗和过继免疫细胞疗法（ACT）。在一项试点临床试验中，已经发现过继性肿瘤浸润淋巴细胞（TIL）细胞疗法能够控制一些接受过多种治疗方案的宫颈癌患者的晚期疾病进展。此外，在一些情况下还确定了可持续的治疗效果。TIL 治疗患者的安全风险很小或至少可以控制。在这篇综述中，我们重点介绍了 TIL 的多功能性，并试图总结提高 TIL 治疗效果的潜在策略，并讨论相关观点。
